[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-viral-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-viral-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,74,97,123,147,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643581","phase-2-a-clinical-trial-evaluating-the-safety-and-efficacy-of-ap1189-versus-placebo-as-an-add-on-to-standard-of-care-in-participants-with-respiratory-insufficiency-expected-to-be-caused-by-infection-with-respiratory-viruses-100643581",false,"NCT07633288","A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses","A Randomized, Double-blind, Multicentre, Placebo-controlled, Proof-of-concept Clinical Trial Evaluating the Safety and Efficacy of the Biased Melanocortin Agonist AP1189 Versus Placebo as an add-on to Standard of Care (SOC) in Participants With RESPIRatory Insufficiency Expected to be Caused by Infection With Respiratory Viruses, Including Influenza, Respiratory Syncytial Virus, and Coronavirus","RESPIRE","Inclusion Criteria:\n\n* Written informed consent has been obtained prior to initiating any study-specific procedures\n* Expected respiratory viral infection, and positive for either SARS-COV-2, Influenza A or B, or RSV as confirmed by a bedside LAF test, qualitative PCR, or quantitative PCR (Q-PCR).\n* Hospitalized with respiratory insufficiency expected to be caused by respiratory viral infection defined by SpO2 ≤ 93 % on ambient air or supplementary oxygen supply via nasal catheter or facial mask (WHO Clinical Progression Scale score 5 or 6). Or in participants with hypercapnic respiratory failure (usually due to COPD) the SpO2 threshold is SpO2 ≤ 85 %.\n* Duration of disease from first symptom\\\u003C 15 days before enrolment\n* Females of childbearing potential using reliable means of contraception or are post-menopausal or are surgically sterilized\n* Females of childbearing potential with a negative pregnancy test at screening and baseline\n* As the morbidity and mortality of respiratory infections are many fold increased in vulnerable participants, vulnerable participants are not excluded but included as subgroups.\n* Screened within 24 hours of hospital admission to the hospital, or within 24 hours of receiving a patient, if the patient is transferred from another hospital or another hospital department due to respiratory distress\n\nExclusion Criteria:\n\n* In the investigator's opinion, progression to death is imminent and inevitable irrespective of the provision of treatment\n* Already meeting any component of the primary composite endpoint at screening, defined as the presence of any of the following: invasive mechanical ventilation, ECMO, cardiovascular organ support (balloon pump or inotropes\u002Fvasopressors), or renal failure (Cockcroft-Gault estimated creatinine clearance \\\u003C15 ml\u002Fmin, haemofiltration or dialysis). Note: participants qualifying under inclusion criterion 8b (pre-existing renal insufficiency or dialysis) are excluded only if they meet any of the other criteria (invasive mechanical ventilation, ECMO, or cardiovascular organ support). Participants who are physically located in an ICU or HDU but do not meet the above physiological criteria are not excluded on that basis alone.\n* Participating in other drug clinical trials\n* Any condition that in the view of the screening physician would suggest that the participant is unable to comply with study protocol and procedures\n* Participants who have initiated treatment within 3 months prior to screening with immunosuppressive or immunomodulatory treatments for chronic autoimmune diseases. Administration of steroids or other immunosuppressive medicines implemented as standard-of-care for the treatment of the respiratory viral infection is acceptable. Asthma\u002FCOPD participants are allowed to use their habitual inhalation spray containing adrenocortical hormone.\n* Pregnant women or nursing (breastfeeding) mothers","ALL","18 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected to be caused by respiratory viral infection.",[27],"Respiratory Viral Infection",[29,30,31],"Influenza","Respiratory Syncytial virus,","Corona virus","RECRUITING","2026-06-08",{"date":35,"type":36},"2026-06-11","ACTUAL",{"date":38,"type":36},"2026-05-01",{"date":40,"type":21},"2027-08-01",{"name":42,"class":43},"SynAct Pharma Aps","INDUSTRY",11,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100637542","assessment-of-the-type-i-ifn-response-in-the-nasal-cavity-during-respiratory-viral-infections-in-a-geriatric-department-100637542","NCT07601412","Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department","RESPIGERIA","Inclusion Criteria:\n\n* Patients admitted to a geriatric ward or participants diagnosed with a PCR-positive infection based on a swab sample taken as part of the REFIPA study (NCT07239830). Nasopharyngeal swab taken for viral detection, where the viral test was carried out as part of standard clinical care (minimum 500 µL required)\n\nExclusion Criteria:\n\n* The patient's objection to the use of their data in this study","60 Years",{"count":54,"type":21},1140,"OBSERVATIONAL","The diagnosis of respiratory viral infections is usually based on testing for pathogens suspected of causing the infection using PCR tests that target the pathogens' DNA or RNA. A specific PCR test is required for each pathogen. In most cases, testing is carried out primarily for three specific viruses (SARS-CoV-2, respiratory syncytial virus (RSV), influenza virus) is carried out as a first-line test. However, numerous viruses can cause these infections (adenovirus, metapneumovirus, rhinovirus, parainfluenza virus, bocavirus, etc.). Consequently, performing a specific PCR test for every virus that could cause respiratory symptoms is not feasible, and viral infections are often under-diagnosed because the screening for viruses is not exhaustive.\n\nTo address this issue, analysing the host response to determine the microbial aetiology of an infection may represent an innovative alternative for the diagnosis of infections. A common feature of all viruses is their ability to induce type I interferons (IFN-I). Thus, measuring this IFN-I response could help direct the diagnosis of respiratory infections towards a viral origin.\n\nFurthermore, the detection of a virus via PCR in a respiratory sample may indicate an active or recent infection, but may also be detected following an infection that occurred several weeks or months earlier. The viral load in the sample is an important factor in distinguishing between these two scenarios but does not always allow for a definitive conclusion (some patients may have low viral loads whilst still having an active infection). It is therefore sometimes difficult to distinguish, using a PCR test that detects the viral genome, between the virus currently replicating and traces of viral genetic material from dead viruses. It is therefore necessary to have markers that can be associated with an active\u002Freplicating infection to aid interpretation in the event of a positive PCR result.\n\nUsing nasopharyngeal swabs collected for the diagnosis of SARS-CoV-2 infection, we were able to demonstrate that it is possible to measure the IFN-I response. These proteins, which possess antiviral properties, are secreted by immune cells during infection to limit viral replication.\n\nThus, the combination of simultaneous testing for the pathogen and the IFN response has made it possible to link the replicative nature of the SARS-CoV-2 virus with IFN-I production.\n\nOur latest research into SARS-CoV-2 has thus led to the identification of a marker of the IFN-I response associated with active viral replication, which we have confirmed using viral culture techniques that detect only live\u002Finfectious virus.\n\nHowever, the IFN-I response may be compromised in older and very old individuals, particularly due to certain comorbidities or treatments, the prevalence of which increases with age.\n\nThe aim of this study is to assess the IFN-I response in the context of respiratory infections caused by various viruses, in a population admitted to a geriatric ward and a population from the REFIPA protocol (NCT07239830), a study designed to establish reference values for nasal and blood interferon scores in uninfected elderly subjects.\n\nThere is a need to improve the diagnosis of viral infections, particularly in geriatric wards where the burden of viral infections is very significant for patients, carers and the organisation of care. Rapid diagnosis of viral infections would enable the optimisation of isolation measures and hygiene protocols within these wards. Furthermore, it is important to validate new markers that could aid in the interpretation of a positive PCR result for respiratory viruses. Some PCR tests can indeed remain positive for several weeks or even months due to the detection of traces of viral genetic material.\n\nThus, new markers indicating an active or recent infection could be useful in facilitating interpretation, alongside other clinical and\u002For virological findings.\n\nThe aim is, by combining different results, to improve the diagnosis of viral infections and to avoid over-diagnosing respiratory viral infections due to a positive PCR result that may in fact correspond to a past infection.",[27],[59,60,61,62],"Respiratory viral infection","Geriatric","Diagnostic","Type I Interferon response","2026-05-15",{"date":65,"type":36},"2026-05-22",{"date":67,"type":36},"2024-01-04",{"date":69,"type":21},"2027-07-31",{"name":71,"class":72},"Hospices Civils de Lyon","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":73},"100498649","phase-1-macrophage-regulation-of-ozone-induced-lung-inflammation-100498649","NCT05773001","Macrophage Regulation of Ozone-Induced Lung Inflammation","MOLI","Inclusion Criteria:\n\n* Individuals between 18-55 yrs. of age (No subject will be excluded from the study on the basis of gender or ethnicity)\n* Individuals with knowledge of prior respiratory viral infection history allowing them to be segregated into one of three cohorts\n\n  * Cohort 1 - No history of respiratory viral infection (defined as no symptoms consistent with respiratory viral infection nor history of a positive respiratory viral test)\n  * Cohort 2 - Documented mild respiratory viral infection (a positive test, either PCR- or antigen-based) but with mild to no symptoms and no evidence of a lower respiratory tract infection (including no hospitalization, and no oxygen use)\n  * Cohort 3 - History of respiratory viral infection and symptoms\u002Fimaging consistent with a lower respiratory tract infection who have recovered, are \\>6 months out from their infection, and have normal lung function (spirometry with FVC, FEV1 and FEV1\u002FFVC)\n\n    * There will be no maximal period from respiratory viral infection for inclusion in the study, the minimal period will be \\>6 months out from infection\n\nExclusion Criteria:\n\n* Individuals with prior respiratory viral pneumonia who have ongoing respiratory symptoms, are still using supplemental oxygen, or have abnormal lung function\n* Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years\n* Pregnant women and women who are presently lactating.\n* Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks\n* College and graduate students or employees who are under direct supervision by any of the investigators in this protocol\n* Alcohol or illicit substance abuse\n* Chronic cardio\u002Fpulmonary respiratory disorders or other medical conditions as determined by the investigator\n* Increased airway hyperresponsiveness at baseline as measured by a positive methacholine challenge response (methacholine PC20 FEV1 \\\u003C 4 mg\u002Fml)\n* Subjects will be requested to refrain from antihistamines, nonsteroidal anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.",true,"55 Years",{"count":84,"type":21},100,[86],"PHASE1","The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.",[27],"2026-05-13",{"date":63,"type":36},{"date":92,"type":36},"2023-05-18",{"date":94,"type":21},"2028-05",{"name":96,"class":72},"Robert Tighe, MD",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":81,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100548189","dime-la-verdad-verify-debunk-and-disseminate-100548189","NCT06417762","Dime La VerDAD: Verify, Debunk, and Disseminate","Inclusion Criteria:\n\n1. 18 years or older\n2. Fluent in English or Spanish\n3. Provide services as a community health worker or similar designation in at least one of the seven communities with high morbidity and mortality due to respiratory virus infections\n4. Have a social media presence (personal or work related)\n\nExclusion Criteria:\n\n1. Plan to stop working as a community health worker or similar designation before spring of 2028 (end of data collection planned)\n2. Do not wish to participate in a social media campaign","99 Years",{"count":105,"type":21},1400,[107],"NA","Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in favor of recommended immunizations in communities with high morbidity and mortality due to respiratory virus infections.\n\nDime La Verdad is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers community health workers to disseminate reliable information about respiratory virus protection strategies through the use of personal narratives on social media. The proposed work will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in principles of health communication, 2) evaluate how diffusion of health messaging is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can encourage informed decision-making to promote evidence-based immunization practices and improve health outcomes.",[29,110,111,112,27],"COVID-19","Communication Research","Health Behavior","2026-02-26",{"date":115,"type":36},"2026-03-02",{"date":117,"type":36},"2024-07-02",{"date":119,"type":21},"2029-04-01",{"name":121,"class":72},"University of Chicago",4,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":73},"100620394","phase-3-phase-iii-clinical-study-evaluating-the-safety-pharmacokinetics-and-efficacy-of-jkn2301-dry-suspension-in-pediatric-patients-aged-2-to-under-12-years-with-influenza-100620394","NCT07357051","Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","Inclusion Criteria:\n\n* Pediatric patients within the specified age range.\n* Clinical presentation consistent with influenza, confirmed by a positive local rapid test or central laboratory PCR test.\n* Presentation for treatment within the early symptomatic phase of influenza illness.\n* Presence of fever and at least one respiratory symptom.\n* Ability to swallow oral suspension.\n* Parent\u002Fguardian and patient (as age-appropriate) able to provide informed consent\u002Fassent.\n\nExclusion Criteria:\n\n* Clinical signs suggestive of severe or complicated influenza infection\n* requiring inpatient management.\n* Presence of a concurrent bacterial infection requiring systemic therapy.\n* Significant immunocompromised, or severe\u002Funcontrolled comorbid conditions.\n* History of hypersensitivity to any component of the investigational products.\n* Use of prohibited medications (including other anti-influenza antivirals) within a specified period prior to enrollment.\n* Recent participation in another interventional clinical trial.\n* Any condition that, in the opinion of the investigator, would jeopardize patient safety or compliance with the study protocol.","2 Years","11 Years",{"count":133,"type":21},177,[135],"PHASE3","The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.",[27],"2026-01-15",{"date":140,"type":36},"2026-01-21",{"date":142,"type":36},"2025-11-07",{"date":144,"type":21},"2026-04-15",{"name":146,"class":43},"Joincare Pharmaceutical Group Industry Co., Ltd",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":153,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100481537","multi-center-molecular-diagnosis-and-host-response-of-respiratory-viral-infections-in-pediatric-transplant-recipients-100481537","NCT05550298","Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients","Recipient Inclusion Criteria\n\n* Less than 18 years at the time of anticipated transplant\n* Participant meets one of the following criteria:\n\n  1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or\n  2. Scheduled to or received solid organ transplant within 7 days before or after enrollment\n* Participant is receiving care at the time of enrollment at one of the study participating institutions.\n* Parent\u002Fguardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.\n\nDonor Inclusion Criteria\n\n* Donor for HCT recipient enrolled on the VIPER study.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\nRecipient Exclusion Criteria\n\nNone\n\nDonor Exclusion Criteria\n\n* Is not an HCT donor for a participant enrolled on the VIPER study.\n* Not available to provide pre-transplant research blood sample.",{"count":154,"type":21},2000,"The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).\n\nPrimary Objective\n\nTo determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.\n\nSecondary Objectives:\n\n* To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors.\n* To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV\u002FPIV3\u002FHMPV\u002FSARS-CoV-2 through one-year post-transplant among survivors .",[157,158,27],"Hematopoietic Cell Transplant","Solid Organ Transplant","2025-09-29",{"date":161,"type":36},"2025-10-02",{"date":163,"type":36},"2022-12-13",{"date":165,"type":21},"2029-08",{"name":167,"class":72},"Arkansas Children's Hospital Research Institute",27,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":81,"sex":17,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100535071","reducing-respiratory-virus-transmission-in-bangladeshi-classrooms-100535071","NCT06247059","Reducing Respiratory Virus Transmission in Bangladeshi Classrooms","Inclusion Criteria:\n\n* Schoolchildren of Bangladesh Government-run primary schools in Dhaka, Bangladesh ages 9 - 12 years, of all gender identifiers (male, female, transgender, prefer not to designate), without specific ethnic selection amongst standard school children of Bangladesh government schools in Dhaka, Bangladesh.\n\nExclusion Criteria:\n\n* School children of non-Bangladesh Government-run primary schools and\u002For schoolchildren who do not attend a Bangladesh Government-run primary school in Dhaka, Bangladesh.\n* School children who are not able to or have a contraindication with the ability to comply with study procedures.","9 Years","12 Years",{"count":178,"type":21},20000,[107],"This study will test if affordable air cleaning devices (box fans with a filter attached and\u002For ultraviolet light lamps) installed in classrooms can reduce the number of viral respiratory illnesses schoolchildren experience.",[182,183,27],"SARS-CoV2 Infection","Influenza Viral Infections",[185,186,187,188,29,189,190,191,192],"Bangladesh","Indoor air quality","Air cleaning","Respiratory viral infections","SARS-CoV2","Air filtration","Ultraviolet germicidal irradiation","Global health","NOT_YET_RECRUITING","2025-03-28",{"date":196,"type":36},"2025-04-02",{"date":198,"type":21},"2025-10",{"date":200,"type":21},"2027-01",{"name":202,"class":72},"Stanford University"]